AACR20: translating oncolytic viruses into the clinic, an interview with Yuman Fong

Written by Yuman Fong (City of Hope, CA, USA)

We spoke with Dr. Yuman Fong (Chief of Surgery, City of Hope, CA, USA) about his recent work presented at the American Association for Cancer Research (AACR; 27–28 April 2020), titled, ‘A first-in-human phase 1 ascending, multiple dose, safety and tolerance study of Vaxinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adult patients with mixed advanced solid tumors (MAST)’. Fong’s research interests over the last 25 years have been designing viruses and cells to be used for anticancer therapy. Can you tell us about your work that will be presented at the AACR Virtual Annual Meeting...

To view this content, please register now for access

It's completely free